Dedicated to Translating Exosome Therapeutics into a Clinical & Commercial Reality
The exosome field is evolving rapidly as scientific understanding grows and the industry quickly approaches the stage of entering clinical trials over the coming years. If the boom in immunotherapies has told us anything about drug development; it’s being first to market is game changing.
The inaugural Exosome Based Therapeutic Development Summit 2019 will unite biotech, academia, pharma and technology providers to accelerate the discovery, development and commercialization of safe and effective exosome based therapeutics. As the race to the clinic intensifies, this summit focuses exclusively on therapeutic applications to help industry leaders and newcomers alike overcome key challenges to improve the end-to-end development of these therapeutics, from discovery through to the delivery of these products to market.
Chief Executive Officer
Chief Business Officer & Head of Strategy
Associate Professor, Laboratory Medicine & Co-Founder & Head, Protein Engineering
Karolinska Institute & Evox Therapeutics
Vice President, Regulatory Affairs & Pharmacovigilance
Professor, Neurology & Geneticist, Neurology & Radiology
Harvard Medical School & Massachusetts General Hospital
Co-Founder & Chief Executive Officer
Aegle Therapeutics Corp.
Chief Executive Officer & Chief Scientific Officer & Vice President, Research & Development
Oncocyclist & BioCardia & Aegle Therapeutics
Co-Founder & Chief Scientific Officer & Professor
ArunA Bio & University of Georgia
Why Are Our Speakers Excited to be Involved?
"Exosome-based therapeutics represent a most promising next generation approach for treating a diverse array of diseases. As we transition from the laboratory to the clinic, this timely meeting will bring academia and industry together, and will provide an exciting platform to showcase current cutting-edge advances in the exosome field”.
Gareth Willis, Instructor, Pediatrics, Boston Children’s Hospital, Harvard Medical School
“Exosomes represent a novel source of therapeutics, however clinical translation presents a range of challenges. This meeting represents an opportunity for discussion and exchange to facilitate the development of exosome products.”
Ian McNiece, Chief Executive Officer & Chief Scientific Officer & Vice President, Research & Development, Oncocyclist & BioCardia & Aegle Therapeutics